Thursday, October 25, 2012

Eisai signs global Agreement with Fundacao oswaldo cruz to begin development for new vaccines and medicines for malaria and neglected tropical disease

Under the global agreement, Eisai and Fiocruz will identify research development collaborations targeting Eisai compounds for indications of malaria and NTDs. For the first collaboration, it has been decided to begin studies on the development of a medicine for cerebral malaria using E6446 and analogs, which are Toll-like receptor 9 (TLR9) antagonists.

Fiocruz is an agency of the Brazilian Ministry of Health with a mission to promote health and social development, to generate and disseminate scientific and technological knowledge, and to be an agent of citizenship. Fiocruz is responsible for the development and production of vaccines, drugs, reagents, and diagnostic kits relevant to public health in Brazil, and is the most active public institution in promoting the development of new drugs for the treatment of NTDs in the South American region. This collaboration is a new partnership model that integrates Fiocruz’s strengths in the research and development of medicines for NTDs in the South American region with Eisai’s compounds and knowledge as a research-based pharmaceutical company, and which will seek to develop new treatments for malaria and NTDs as early and efficiently as possible.
Eisai is determined to be proactive in improving access to medicines worldwide through partnerships with governments, international organizations, and other non-profit private sector organizations. Eisai is a signatory to the London Declaration, a coordinated effort to eliminate ten NTDs by 2020 through the largest global public-private partnership to date. As part of its commitment under the Declaration, Eisai has entered into this partnership with Fiocruz, and has also agreed to produce at its Vizag Plant in India 2.2 billion tablets of diethylcarbamazine (DEC), a lymphatic filariasis medicine currently in short supply globally, and supply it to the World Health Organization (WHO) free of charge from 2013.
As it expands its business in both emerging and developing nations in this era of great globalization, Eisai considers its contributions to the economic development and expansion of the middle-income class through the enhancement of health and welfare in these countries as a form of long-term investment for future growth. Going forward, Eisai is committed to taking proactive steps to address issues related to access to medicines, including NTDs, as it seeks to make further contributions to increase the benefits provided to patients and their families worldwide.

Enter your email address:

Delivered by FeedBurner

No comments:

Post a Comment